| __timestamp | Amphastar Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 2983000000 |
| Thursday, January 1, 2015 | 46974000 | 3426000000 |
| Friday, January 1, 2016 | 47298000 | 3398000000 |
| Sunday, January 1, 2017 | 50918000 | 3878000000 |
| Monday, January 1, 2018 | 58044000 | 4056000000 |
| Tuesday, January 1, 2019 | 63109000 | 4381000000 |
| Wednesday, January 1, 2020 | 65157000 | 5151000000 |
| Friday, January 1, 2021 | 68920000 | 5246000000 |
| Saturday, January 1, 2022 | 66592000 | 5673000000 |
| Sunday, January 1, 2023 | 80393000 | 6090000000 |
| Monday, January 1, 2024 | 6091000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Gilead Sciences, Inc. and Amphastar Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead's SG&A expenses surged by over 100%, peaking at approximately $6.09 billion in 2023. This reflects their aggressive market expansion and strategic investments. In contrast, Amphastar's expenses grew by nearly 99%, reaching around $80 million in the same year, indicating a steady yet cautious growth approach. These trends highlight the contrasting strategies of a biotech giant versus a smaller pharmaceutical player. As the industry faces new challenges and opportunities, monitoring such financial metrics provides valuable insights into corporate strategies and market positioning.
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and ImmunityBio, Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.